USRM Chief Science Officer Discusses Health Freedom Surrounding Autologous Stem Cell Industry
SUNRISE, FL – November 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, has appeared on the Robert Scott Bell Show to talk about health freedom and autologous stem cell therapy. The interview can be listened to in its entirety here.
Autologous (a patient’s own) stem cell therapy is currently being researched in autoimmune, neurological, orthopedic and degenerative conditions. As one of the world’s leaders in autologous stem cell therapy, Dr. Comella is extensively published in peer reviewed scientific publications indexed on Pubmed in the field of regenerative medicine. This year thus far, she has published several peer reviewed papers demonstrating the benefits of autologous stem cell therapy for chronic conditions, including decubitus ulcers (perpetual sores common in spinal injury patients and the elderly); meniscal tears, and psoriasis. Chronic conditions can cause chronic pain — the source of a national opioid epidemic which The New York Times reports is the leading cause of death for Americans under the age of 50.
Through Dr. Comella’s leadership, she and her team have trained and certified more than 700+ physicians worldwide in stem cell therapy. She was named number 24 on Terrapin’s list of the Top 50 Global Stem Cell Influencers and no. 1 on the Academy of Regenerative Practices’ list of Top 10 Stem Cell Innovators. She also made the list of Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com, one of the most visited natural health websites in the world.
“Dr. Comella is taking an important stand to ensure your stem cells are not declared a drug” said Robert Scott Bell. “We will continue to monitor the FDA’s and Dr. Comella’s efforts in this endeavor.”
“It is important to continue informing Americans about adipose-derived, autologous (a patient’s own) stem cell therapy and its availability — today — for managing the repair of tissue damage, chronic pain and other conditions,” said Dr. Comella. “Robert is a voice for health freedom, and it was great to have the opportunity to share with him our concerns in attempting to prevent Americans from having access to the healing cells in their own bodies.”
Autologous stem cell therapy involves taking a small sample of patient’s fat and separating the healing stem cells from the fat or adipose tissue. Fat tissue has a higher amount of stem cells than bone marrow and is much less invasive to retrieve. The healing stem cells are then re-injected locally into a joint or used intravenously for systemic circulation where they may repair damaged tissue in the body. Once the stem cells are separated out from the patient’s own fat, they are simply relocated in their body.
Six days a week, Robert Scott Bell empowers his listeners with healing principles. He hosts two hours of informational radio dealing with everyday health issues from the perspective of alternative/holistic health care. He also fearlessly tackles the tough issues including confronting government and corporations who would stand in the way of health freedom. Bell has personally overcome numerous chronic diseases using natural healing principles, and has dedicated his life to revealing the healing power within all of us. He is a well-known and respected member of the health community and has access to guests from every specialty and practice to better equip listeners to heal themselves from the inside out.
U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.